Discover the role of vitamin B in AMD supplements and download the flowchart outlining the steps of mitochondrial dysfunction in AMD progression.

Age-related macular degeneration (AMD) remains a leading cause of irreversible vision loss and is now understood as a multifactorial disease characterized by oxidative stress, mitochondrial dysfunction, chronic inflammation, and vascular compromise.

The Age-Related Eye Disease Studies (AREDS and AREDS2) established the standard of care for intermediate AMD, demonstrating an approximately 25% reduction in progression to advanced disease with targeted antioxidant and mineral supplementation. ^1,2

Increasingly, AMD is recognized as involving cellular energy failure and metabolic stress, with elevated homocysteine emerging as a potentially modifiable risk marker. Together, mitochondrial dysfunction and homocysteine-mediated vascular injury may act upstream of several downstream features of disease, offering an opportunity to expand beyond traditional antioxidant-based strategies.

AREDS/AREDS2: The foundation

AREDS demonstrated that vitamins C and E, beta-carotene, and zinc reduce progression to advanced AMD.¹ AREDS2 improved safety by replacing beta-carotene with lutein and zeaxanthin while maintaining efficacy.²

These trials validated nutrition as disease-modifying therapy—but did not address upstream metabolic contributors such as mitochondrial dysfunction or homocysteine dysregulation.

Mitochondrial dysfunction: An early driver

The post Why B Vitamins Are The Cornerstone of Next-Generation AMD Supplements appeared first on Macular Degeneration Association.